Dimensional Fund Advisors LP Has $1.25 Million Holdings in Progenics Pharmaceuticals, Inc. (PGNX)
Dimensional Fund Advisors LP boosted its holdings in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 30.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 170,439 shares of the biotechnology company’s stock after purchasing an additional 39,736 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Progenics Pharmaceuticals were worth $1,254,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of PGNX. State Street Corp increased its stake in Progenics Pharmaceuticals by 42.7% in the 2nd quarter. State Street Corp now owns 3,708,788 shares of the biotechnology company’s stock worth $25,186,000 after buying an additional 1,110,067 shares in the last quarter. Hikari Power Ltd purchased a new stake in Progenics Pharmaceuticals in the 3rd quarter worth $1,472,000. Vanguard Group Inc. increased its stake in Progenics Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,300,478 shares of the biotechnology company’s stock worth $29,200,000 after buying an additional 167,708 shares in the last quarter. Eagle Asset Management Inc. increased its stake in Progenics Pharmaceuticals by 3.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 4,166,919 shares of the biotechnology company’s stock worth $32,210,000 after buying an additional 154,553 shares in the last quarter. Finally, Ardsley Advisory Partners increased its stake in Progenics Pharmaceuticals by 34.7% in the 2nd quarter. Ardsley Advisory Partners now owns 510,000 shares of the biotechnology company’s stock worth $3,460,000 after buying an additional 131,500 shares in the last quarter. Institutional investors and hedge funds own 84.65% of the company’s stock.
A number of brokerages have issued reports on PGNX. BidaskClub lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. Zacks Investment Research lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. ValuEngine lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $15.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, January 17th. Two analysts have rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $12.35.
ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/dimensional-fund-advisors-lp-has-1-25-million-holdings-in-progenics-pharmaceuticals-inc-pgnx/1856785.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.